{"url_path":"/sec/aura/8-k/2026-06-11/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-11","source_url":"https://www.sec.gov/Archives/edgar/data/1501796/0001193125-26-267676-index.html","accession_number":"0001193125-26-267676","cik":"0001501796","ticker":"AURA","issuer_name":"Aura Biosciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1501796/0001193125-26-267676-index.html","primary_entity_key":"0001501796","primary_entity_name":"Aura Biosciences, Inc."},"word_count":328,"has_tables":true,"body_markdown":"Item 5.07 Submission of Matters to a Vote of Security Holders.\n\n \n\nOn June 11, 2026, Aura Biosciences, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The proposals set forth below were submitted to the stockholders at the Annual Meeting, with each such proposal described in the Company’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 20, 2026.\n\nThe number of shares of the Company’s common stock, par value $0.00001 per share (“Common Stock”), entitled to vote at the Annual Meeting was 64,199,778. The number of shares of Common Stock present or represented by valid proxy at the Annual Meeting was 52,784,744. The number of votes cast for and against and the number of abstentions and broker non-votes with respect to each proposal voted upon at the Annual Meeting are set forth below.\n\nProposal 1 - Election of Directors\n\nThe Company’s stockholders elected the two (2) director nominees below to the Company’s Board of Directors as Class II directors to serve until the 2029 Annual Meeting of Stockholders of the Company and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal.\n\nDirector Nominee\n\nVotes For\n\nVotes Withheld\n\nBroker\nNon-Votes\n\nDavid Johnson\n\n34,542,193\n\n \n\n \n\n \n\n6,628,297\n\n \n\n \n\n \n\n11,614,254\n\nTeresa Marie Bitetti\n\n40,526,332\n\n \n\n \n\n \n\n644,158\n\n \n\n \n\n \n\n11,614,254\n\n \n\nProposal 2 - Ratification of Appointment of Independent Registered Accounting Firm\n\nThe Company’s stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026.\n\nVotes For\n\n \n\nVotes Against\n\n \n\nAbstentions\n\n52,752,601\n\n \n\n17,348\n\n \n\n14,795\n\n \n\nThere were zero broker non-votes regarding this proposal.\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\n \n\nAura Biosciences, Inc.\n\n \n\n \n\n \n\n \n\nDate:\n\nJune 11, 2026\n\nBy:\n\n/s/ Natalie Holles\n\n \n\n \n\n \n\nNatalie Holles\n Chief Executive Officer and President\n\n(Principal Executive Officer)"}